Amisulpride 50mg Tablets
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Amisulpride 50 mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 50 mg amisulpride
Excipients: 23.75 mg lactose/tablet
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet
White, round (6 mm diameter), bi-convex tablet with score line. The tablet can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders with:
- positive symptoms such as delusions, hallucinations, thought disorders, hostility, suspiciousness
- negative symptoms (deficit syndrome) such as blunted affect, emotional and social withdrawal.
This includes patients with predominant negative symptoms.
4.2 Posology and method of administration
Posology
For acute psychotic episodes, oral doses between 400 mg/day and 800 mg/day are recommended. In individual cases, the daily dose may be increased up to 1200 mg. Doses above 1200 mg/day have not been extensively evaluated for safety and therefore should not be used. No specific titration is required when initiating the treatment with amisulpride. Doses should be adjusted according to individual response.
For patients with mixed positive and negative symptoms, doses should be adjusted to obtain optimal control of positive symptoms in example between 400-800mg/day.
Maintenance treatment should be established individually with the minimally effective dose.
For patients characterised by predominant negative symptoms, oral doses between 50 mg/day and 300 mg/day are recommended. Doses should be adjusted individually.
Amisulpride can be administered once daily at oral doses up to 300 mg, higher doses should be administered bid.
The minimum effective dose and appropriate strength tablets should be used.
Special populations
Older people (over 65 years): The safety of amisulpride has been examined in a limited number of older people. Amisulpride should be used with particular caution because of a possible risk of hypotension and sedation. Reduction in dosage may also be required because of renal insufficiency.
Paediatric population: The efficacy and safety of amisulpride from puberty to the age of 18 years have not been established. There are limited data available on the use of amisulpride in adolescents in schizophrenia. Therefore, the use of amisulpride from puberty to the age of 18 years is not recommended; in children up to puberty amisulpride is contraindicated, as its safety has not yet been established (see section 4.3).
Patients with renal impairment: Amisulpride is eliminated by the renal route. In renal insufficiency, the dose should be reduced to half in patients with creatinine clearance (CRCl) between 30-60 ml/min and to a third in patients with CRcL between 10-30 ml/min.
As there is no experience in patients with severe renal impairment (CRCL < 10 ml/min) particular care is recommended in these patients (see section 4.4).
Patients with hepatic impairment: Since amisulpride is weakly metabolised a dosage reduction should not be necessary.
Duration of treatment
Data from controlled clinical trials covering a period of 1 year is available. The duration of treatment should be determined by the treating physician.
Method of administration
Amisulpride can be administered with or without food. The tablets should be taken without chewing with a sufficient amount of water.
Note
For doses not realisable/practicable with this strength, other strengths of this medicinal product are available.
4.3 Contraindications
- hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- concomitant prolactin-dependent tumours (e.g. pituitary gland prolactinomas or breast cancer)
- phaeochromocytoma
- children before the onset of puberty
- lactation (see section 4.6)
- combination with levodopa (see section 4.5)
4.4 Special warnings and precautions for use
As with other antipsychotics, neuroleptic malignant syndrome, a potentially fatal complication, characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated CPK, may occur. In the event of hyperthermia, particularly with high daily doses, all antipsychotic medicinal products including amisulpride should be discontinued.
Hyperglycaemia has been reported in patients treated with some atypical antipsychotic agents, including amisulpride, therefore patients with an established diagnosis of diabetes mellitus or with risk factors for diabetes who are started on amisulpride, should get appropriate glycaemic monitoring.
Amisulpride is eliminated by the renal route. In cases of renal insufficiency, the dose should be decreased or intermittent treatment could be considered (see section 4.2).
Amisulpride may lower the seizure threshold. Therefore patients with a history of epilepsy should be closely monitored during amisulpride therapy.
In older people (over 65 years), amisulpride, like other antipsychotics, should be used with particular caution because of a possible risk of hypotension or sedation. Reduction in dosage may also be required because of renal insufficiency.
As with other antidopaminergic agents, caution should be also exercised when prescribing amisulpride to patients with Parkinson's disease since it may cause worsening of the disease. Amisulpride should be used only if antipsychotic treatment cannot be avoided.
Acute withdrawal symptoms including nausea, vomiting and insomnia have very rarely been described after abrupt cessation of high doses of antipsychotics. Recurrence of psychotic symptoms may also occur, and the emergence of involuntary movement disorders (such as akathisia, dystonia and dyskinesia) has been reported. Therefore, gradual withdrawal of amisulpride is advisable.
Leukopenia, neutropenia and agranulocytosis have been reported with antipsychotics, including amisulpride. Unexplained infections or fever may be evidence of blood dyscrasia (see section 4.8), and requires immediate haematological investigation.
Prolongation of the QT interval
Caution should be exercised when amisulpride is prescribed in patients with known cardiovascular disease or family history of QT prolongation and concomitant use with antipsychotics should be avoided.
Stroke
In randomized clinical trials versus placebo performed in a population of older people with dementia and treated with certain atypical antipsychotic drugs, a 3-fold increase of the risk of cerebrovascular events has been observed. The mechanism of such risk increase is not known. An increase in the risk with other antipsychotic drugs, or other populations of patients cannot be excluded. Amisulpride should be used with caution in patients with stroke risk factors.
Older people with dementia
Older people with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotics, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death in clinical trials with atypical antipsychotics were varied, most of the deaths appeared to be either cardiovascular (e.g., hearth failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotics may increase mortality.
The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.
Amisulpride is not licensed for the treatment of dementia-related behavioural disturbances.
Venous thromboembolism
Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with amisulpride and preventive measures undertaken.
Lactose
Amisulpride tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
4.5 Interaction with other medicinal products and other forms of interaction
Contraindicated combinations
- Levodopa: reciprocal antagonism of effects between levodopa and antipsychotics
- Amisulpride may oppose the effect of dopamine agonists e.g. bromocriptine, ropinirole
Combinations not recommended
Amisulpride may enhance the central effects of alcohol. Therefore, alcohol should not be consumed during treatment.
Combinations to be taken into account
Concomitant use of the following agents can lead to potentiation of the effect:
- CNS depressants including narcotics, anaesthetics, analgesics, sedative H1 antihistamines, barbiturates, benzodiazepines and other anxiolytic drugs, clonidine and derivatives
- antihypertensive drugs and other hypotensive medicinal products
- caution is advised when prescribing amisulpride with medicines known to prolong the QT interval, e.g., class IA antiarrythmics (e.g., quinidine, disopyramide) and class III antiarrhythmics (e.g. amiodarone, sotalol), some antihistaminics, some other antipsychotics and antimalarials (e.g., mefloquine) (see section 4.4).
4.6 Fertility, pregnancy and lactation
Pregnancy
In animals, amisulpride did not show reproductive toxicity and no teratogenic effects of amisulpride were noted.
Very limited clinical data on exposed pregnancies are available. Therefore, the safety of amisulpride during human pregnancy has not been established.
Use of this medicinal product is not recommended during pregnancy unless the benefits justify the potential risks.
Neonates exposed to antipsychotics (including amisulpride) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.
Breast-feeding
It is not known whether amisulpride is excreted in breast milk, breast-feeding is therefore contra-indicated.
Fertility
In animals a decrease in fertility linked to the pharmacological effects of amisulpride (prolactin mediated effect) was observed.
Women of childbearing potential
Effective contraception should be fully discussed with the physician prior to treatment.
4.7 Effects on ability to drive and use machines
This medicinal product can have minor or moderate influence on the ability to drive and use machines.
Even used as recommended, amisulpride may cause somnolence so that the ability to drive vehicles or operate machinery can be impaired (see section 4.8). This effect is enhanced by the consumption of alcohol.
4.8 Undesirable effects
The following frequency estimates are used in assessing adverse effects:
Very common: Common: Uncommon: Rare:
Very rare:
Not known:
( >1/10)
(>1/100 to <1/10)
(>1/1,000 to <1/100)
(>1/10,000 to <1/1,000)
(<1/10,000)
(cannot be estimated from the available data)
CLINICAL TRIALS DATA
The following adverse reactions have been observed in controlled clinical trials. It should be noted that in some instances it can be difficult to differentiate adverse reactions from symptoms of the underlying disease.
Adverse Drug Reactions (ADRs) by System Organ Class and Frequency
|
MedDRA System Organ Class |
Frequency |
ADRs |
|
Immune system disorders |
Uncommon |
Allergic reaction |
|
Endocrine disorders |
Common |
Hyperprolactinaemia1 |
|
Metabolism and nutrition disorders |
Uncommon |
Hyperglycemia (see section 4.4) |
|
Psychiatric disorders |
Common |
Insomnia, anxiety, agitation, orgasmic dysfunction |
|
Nervous system disorders |
Very common |
Extrapyramidal symptoms (tremor, rigidity, hypokinesia, hypersalivation, akathisia, dyskinesia)2 |
|
Common |
Acute dystonia (spasm torticollis, oculogyric crisis, trismus)3, somnolence | |
|
Uncommon |
Tardive dyskinesia (characterized by rhythmic, involuntary movements primarily of the tongue and/or face)4, seizures | |
|
Cardiac disorders |
Uncommon |
Bradycardia |
|
Vascular disorders |
Common |
Hypotension |
|
Gastrointestinal disorders |
Common |
Constipation, nausea, vomiting, dry mouth |
|
Reproductive system and breast disorders |
Common |
Galactorrhoea, amenorrhoea, gynaecomastia, breast pain and erectile dysfunction |
|
General disorders and administration site conditions |
Very rare |
Acute withdrawal symptoms (including nausea, vomiting and insomnia )5, recurrence of psychotic symptoms, emergence of involuntary movement disorders (such as akathisia, dystonia and dyskinesia) (see section 4.4) |
|
Investigations |
Common |
Weight gain |
These symptoms are generally mild at optimal dosages and partially reversible without discontinuation of amisulpride upon administration of antiparkinsonian medication. The incidence of extrapyramidal symptoms which is dose related, remains very low in the treatment of patients with predominantly negative symptoms with doses of 50-300 mg/day.
|
Uncommon |
Elevations of hepatic enzymes, mainly transaminases | |
|
1 Reversible a: |
Iter discontinuation of amisulpride. | |
2
3 This is reversible without discontinuation of amisulpride upon treatment with an antiparkinsonian agent.
4 Occurs usually after long term administration of amisulpride. Antiparkinsonian medication is ineffective or may induce aggravation of the symptoms.
5 After abrupt cessation of high doses of amisulpride.
POST MARKETING DATA
In addition, cases of the following adverse reactions have been reported through spontaneous reporting only:
|
Adverse Drug Reactions (AD |
Rs) by System Organ Class and Frequency | |
|
MedDRA System Organ Class |
Frequency |
ADRs |
|
Blood and lymphatic system disorders |
Not known |
Leukopenia, neutropenia, agranulocytosis (see section 4.4) |
|
Nervous system disorders |
Not known |
Neuroleptic malignant syndrome (a potentially |
|
fatal complication, see section 4.4) | ||
|
Cardiac disorders |
Not known |
QT interval prolongation and ventricular arrhythmias such as torsade de pointes, Ventricular tachycardia, which may result in ventricular fibrillation or cardiac arrest, Sudden death, (see section 4.4) |
|
Vascular disorders |
Not known |
Cases of venous thromboembolism, including cases of pulmonary embolism, sometimes fatal, and cases of deep vein thrombosis have been reported with antipsychotic drugs. |
|
Skin and subcutaneous tissue disorders |
Not known |
Angioedema, urticaria |
|
Pregnancy, puerperium and perinatal conditions |
Not known |
Drug withdrawal syndrome neonatal (see section 4.6) |
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any
suspected adverse reactions via Yellow Card Scheme: www.mhra.gov.uk/yellowcard.
4.9 Overdose
Symptoms
Experience with amisulpride in overdose is limited. Exaggeration of the known pharmacological effects of amisulpride has been reported. These include drowsiness and sedation, coma, hypotension and extrapyramidal symptoms.
Fatal outcomes have been reported mainly in combination with other psychotropic agents.
Management
In cases of acute overdose, the possibility of multiple drug intake should be considered.
Since amisulpride is weakly dialysed, haemodialysis is of no use to eliminate it. There is no specific antidote to amisulpride. Appropriate supportive measures should therefore be instituted with close supervision of vital functions including continuous cardiac monitoring due to the risk of prolongation of the QT interval until the patient recovers.
If severe extrapyramidal symptoms occur, anticholinergic agents should be administered.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: antipsychotics: benzamides ATC code: N05AL05
Amisulpride binds selectively with a high affinity to human dopaminergic D2/D3 receptor subtypes whereas it is devoid of affinity for D1, D4 and D5 receptor subtypes. Unlike classical and atypical antipsychotics, amisulpride has no affinity for serotonin, alpha-adrenergic, histamine H1 and cholinergic receptors. In addition, amisulpride does not bind to sigma sites. In animal studies, at high doses, amisulpride blocks dopamine receptors located in the limbic structures in preference to those in the striatum. At low doses it preferentially blocks pre-synaptic D2/D3 receptors, producing dopamine release responsible for its disinhibitory effects.
This pharmacological profile explains the clinical efficacy of amisulpride against both negative and positive symptoms of schizophrenia.
5.2 Pharmacokinetic properties
Absorption
In man, amisulpride shows two absorption peaks: one which is attained rapidly, one hour post-dose and a second between 3 and 4 hours after administration. Corresponding plasma concentrations are 39 ± 3 ng/ml and 54 ± 4 ng/ml after a 50 mg dose.
A carbohydrate rich meal (containing 68% fluids) significantly decreases the AUCs, Tmax and Cmax of amisulpride but no changes were seen after a high fat meal. However, the significance of these findings in routine clinical use is not known.
Distribution
The volume of distribution is 5.8 l/kg bodyweight, plasma protein binding is low (16%) and no drug interactions are suspected.
Biotransformation
Absolute bioavailability is 48%. Amisulpride is weakly metabolised: two inactive metabolites, accounting for approximately 4% of the dose, have been identified. There is no accumulation of amisulpride and its pharmacokinetics remain unchanged after the administration of repeated doses. The elimination half-life of amisulpride is approximately 12 hours after an oral dose.
Elimination
Amisulpride is eliminated unchanged in the urine. Fifty percent of an intravenous dose is excreted via the urine, of which 90% is eliminated in the first 24 hours. Renal clearance is in the order of 20 l/h or 330 ml/min.
Hepatic impairment
Since amisulpride is weakly metabolised a dose reduction should not be necessary in patients with hepatic insufficiency.
Renal impairment
The elimination half-life is unchanged in patients with renal insufficiency while systemic clearance is reduced by a factor of 2.5 to 3. The AUC of amisulpride in mild renal failure increased two fold and almost tenfold in moderate renal failure (see section 4.2). Experience is however limited and there is no data with doses greater than 50 mg.
Amisulpride is very weakly dialysed.
Older people (over 65 years)
Limited pharmacokinetic data in this patient group show that a 10-30% rise occurs in Cmax, T% and AUC after a single oral dose of 50 mg. No data are available after repeat dosing.
5.3 Preclinical safety data
An overall review of the completed safety studies indicates that amisulpride is devoid of any general, organ-specific, teratogenic, mutagenic or carcinogenic risk. Changes observed in rats and dogs at doses below the maximum tolerated dose are either pharmacological effects or are devoid of major toxicological significance under these conditions. Compared with the maximum recommended dose in man, maximum tolerated doses are 2 and 7 times greater in the rat (200 mg/kg/day) and dog (120 mg/kg/day) respectively in terms of AUC. No carcinogenic risk, relevant to man, was identified in the rat at up to 1.5 to 4.5 times the expected human AUC. A mouse carcinogenicity study (120 mg/kg/day) and reproductive studies (160, 300 and 500 mg/kg/day respectively in rat, rabbit and mouse) were performed. The exposure of the animals to amisulpride during these latter studies was not evaluated.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose monohydrate Magnesium stearate Methylcellulose Microcrystalline cellulose Sodium starch glycolate (type A)
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
3 years
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
Nature and contents of container
6.5
PVC/Aluminium blister
Pack sizes of 10, 12, 14, 20, 21, 30, 42, 50, 60, 98, 100, 150 and 198 tablets Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements.
7 MARKETING AUTHORISATION HOLDER
Sandoz Ltd.
Frimley Business Park,
Frimley, Camberley, Surrey,
GU16 7SR.
8 MARKETING AUTHORISATION NUMBER(S)
PL 04416/1278
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
21/06/2010
10 DATE OF REVISION OF THE TEXT
08/01/2015